[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].

Abstract excerpt

Myelofibrosis(MF) is a type of myeloprolifirative neoplasms which is difficult to be treated. With the discovery of V617F mutation site in Janus kinase 2 (JAK2), JAK inhibitor provides a new treatment strategy for patients with myelofibrosis. Since 2011 the FDA in USA approved the first generation of JAK inhibitor Ruxolitinib for marketing, a growing number of JAK inhibitors have been entering into the clinical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK2 gene
• Share to Hematopoietic Stem Cell Transplantation
• Share to Janus Kinase 2